


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  B30B 11/00, 15/02		A1	(11) International Publication Number: WO 94/00291  (43) International Publication Date: 6 January 1994 (06.01.94)
(21) International Application Number:	PCT/GB93/01375		(74) Agent: WRIGHT, Robert, Gordon, McRae; Fisons plc, 12 Derby Road, Loughborough, Leicestershire LE11 0BB (GB).
(22) International Filing Date:	30 June 1993 (30.06.93)		
(30) Priority data:	9213874.2	30 June 1992 (30.06.92)	GB
(71) Applicant <i>(for all designated States except US)</i> :	FISONS PLC [GB/GB]; Fison House, Princes Street, Ipswich, Suffolk IP1 1QH (GB).		
(72) Inventors; and			
(75) Inventors/Applicants <i>(for US only)</i> :	LIVESLEY, David, John [GB/GB]; 5 Cotterall Lane, Elsworth, Cambridgeshire CB3 8JR (GB). GAYLOR, Ian, Michael, Daines [GB/GB]; Lovdon House, Gelston, Nr. Grantham, Lincolnshire NG32 2HE (GB).		
Published <i>With international search report.</i>			

**(54) Title: PROCESS FOR PRODUCTION OF MEDICAMENT FORMULATIONS**

## (57) Abstract

A process for the production of compacted bodies of powdered medicament is disclosed, said process comprising the steps of: a) positioning expansible means along the longitudinal axis of the mould; b) placing loose powdered medicament in the mould; and c) expanding the expansible means perpendicularly to the longitudinal axis of the mould. An apparatus for use in the process according to the invention and medicament compacts formed by said process are also disclosed.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FJ	Finland				

## PROCESS FOR PRODUCTION OF MEDICAMENT FORMULATIONS

This invention relates to a novel process for the production of a compacted body of powdered medicament, especially powdered inhalation medicament, referred to herein as a "medicament compact", of the type disclosed in European Patent Application 407028.

The administration by inhalation of medicaments in dry powder form is well known. Devices for the metering and dispensing of measured doses of medicament from a reservoir have also been described previously, for example, in UK Patent No. 2041763 and US Patent No. 2587215. Such devices typically comprise a medicament reservoir and a metering chamber with a volume chosen such that, when filled, the chamber contains the desired weight of medicament for one dose. Filling of the metering chamber is generally accomplished under the influence of gravity, the chamber typically being located at the bottom of the reservoir. Such devices have the disadvantage that variations in the density of the metered powder can easily occur resulting in inaccurate or inconsistent dosing. The packing density of the powder may also depend on the weight of powder remaining in the reservoir, leading to a gradual reduction in the dose delivered by the device. In addition, the dose metered is strongly dependent on the orientation of the device.

European Patent Application 407028 discloses a device which overcomes the disadvantages of other dry powder devices by the use of a metering means which relies not on gravitational force to fill a metering chamber, but on abrasion of a compacted body of powdered medicament. This application contemplated the use of hydraulic presses and the like in the production of the medicament compacts, by which pressure would be applied in the direction of a longitudinal axis of a sample of powdered medicament. Although this is satisfactory in many cases, in others there is a variation in the density of the medicament compact from point to point. Since the device of European Patent Application No. 407028 (in which the medicament compacts are adapted for use) functions by abrading a fixed volume of the medicament compact, it is important that the density of medicament throughout the compact is as uniform as possible. If the density is uniform then slices of medicament of the same thickness abraded from the compact will contain the same amount of medicament, thus ensuring that the correct dosage of medicament is consistently administered to a patient.

We have now found a novel process for the production of medicament compacts

which overcomes or substantially mitigates the problems encountered in processes known from the prior art.

According to the present invention, there is provided a process for the production of a medicament compact, which comprises the steps of:

- 5        a)     positioning expandible means along the longitudinal axis of a mould;
- b)     placing loose powdered medicament in the mould; and
- c)     expanding the expandible means perpendicularly to the longitudinal axis of the mould.

Steps a) and b) may be performed in either order or simultaneously, however,  
10 we prefer them to be performed in the order shown above.

The powdered medicament is preferably metered into the mould, e.g. by weighing the desired amount of medicament. Alternatively, medicament compacts of the desired total mass may be produced by cutting to the appropriate length.

After performing steps a) and b), or during step b), it is preferable to vibrate the  
15 mould assembly and/or action a levelling device. This ensures that the medicament has settled to a level height i.e. that the top surface of the medicament is even, and is of known volume prior to compaction. Vibration of the mould assembly may be achieved using the base unit of a vibratory bowl feeder, this provides axial vibration of adjustable amplitude.

20       During vibration of the mould assembly it is desirable that any loose parts of the assembly should be held in position, this may be accomplished by using a vacuum to hold such parts in place.

Suitable expandible means for use in the process according to the invention  
25 include an expandible mandrel, for example, a cylindrical mandrel capable of radial expansion. The cylindrical mandrel may comprise a plurality of segments capable of radial movement, in the retracted state the segments form a complete cylinder and in the expanded state gaps are present between the segments. The mandrel preferably has from 2 to 12, for example, 6 segments. When the medicament compact is to be administered from a device according to European Patent Application 407028 which, for  
30 a single dose, abrades a cylindrical compact for a predetermined angle of less than 360° around the longitudinal axis, then the mandrel preferably has the same number of segments as there are doses in a 360° rotation about the longitudinal axis of the compact. For example if the device abrades the compact for 60° about the longitudinal

axis for a single dose then the expanding mandrel preferably has 6 segments. This minimises the effects of any irregularities in the internal configuration of the compact.

Outward radial movement of the segments may be produced by a wedging action using e.g. pistons and/or by inflation of a bag placed at the centre of the mandrel.

- 5 Inflation of the bag may be achieved using compressed gas, e.g. air; or hydraulically.

The degree of expansion of the mandrel will depend upon the desired size and density of the medicament compact, for example, the mandrel may expand from a diameter of 16 mm to 20 mm.

The outer surface of the mandrel is preferably covered by an elastomeric sleeve.

- 10 The sleeve prevents ingress of powder into the expansible means. The elastomeric sleeve may be made of any material which exhibits a suitable degree of elasticity, e.g. vulcanised rubber. In addition to a suitable degree of elasticity, the elastomeric material should be non-toxic and preferably has a high degree of tear resistance and is easily moulded. The elastomeric material is preferably a vulcanised elastomer suitable for
- 15 drug contact, for example, a natural rubber or silicone rubber compound.

As the elastomeric sleeve expands radially its thickness reduces and there may be a tendency for it to shorten in length. It is desirable for the sleeve to remain a constant length, so it is preferable that the ends of the sleeve turn inwards towards the longitudinal axis of the mandrel. This may help to prevent axial shortening in two ways,

- 20 firstly, it grips onto the ends of the mandrel segments, thus restricting shrinkage by shear forces; secondly, as it expands and its outer diameter increases, radial tension is generated which tries to pull the cylinder edges in towards the axis.

As the mandrel expands the elastomeric sleeve may tend to flatten across the gaps which open up between the segments. This effect may be reduced by applying a

- 25 pressure, e.g. of 5 bar, to the interior of the elastomeric sleeve, thus allowing it to be inflated relative to the expansible means. At other times it is desirable to maintain a lower pressure, e.g. 0.5 bar, within the elastomeric sleeve, this pressure helps to prevent the ingress of powder into the expansible mandrel.

Other expansible means which may be mentioned include inflatable means such

- 30 as inflatable bags, inflation of the bag may be achieved using compressed gas, e.g. air; or hydraulically.

The pressure exerted by the expansible means will depend upon the desired density of medicament in the compact (by density of medicament we mean the mass of

medicament per unit volume). However, the expandible means typically exerts a pressure of from  $60 \times 10^3$  to  $2000 \times 10^3$  N.m $^{-2}$ , for example  $900 \times 10^3$  N.m $^{-2}$ .

The density of the medicament in the compacts produced according to the invention will depend *inter alia* upon medicament used. However, a typical compact 5 may have a density of from 0.1 to 1.5 g/cm $^3$ , preferably from 0.4 to 0.8 g/cm $^3$ . The density of the medicament compacts produced according to the invention may be determined by weighing a fixed volume of medicament abraded from the compact.

We prefer the medicament compact to be formed in a mould which subsequently forms all or part of the medicament reservoir of a medicament inhalation device. Thus, 10 after compaction the compact and mould are in a form suitable for direct transfer to the inhalation device. By obviating the need to remove the compact from the mould prior to its insertion in the device, handling of the medicament compact, and hence the risk of contamination or loss of medicament through premature abrasion, is reduced.

After production the compact may be transferred directly to the inhalation device 15 from which it is to be administered, alternatively the compacts may be packaged separately thus providing replacement medicament reservoirs for the device from which they are to be administered.

According to a second aspect, the invention provides the novel apparatus described herein for carrying out the first aspect of the invention.

20 Therefore we provide an apparatus for the production of a medicament compact from loose powdered medicament which comprises:

- a) a mould having a longitudinal axis adapted to receive loose powdered medicament,
- b) expandible means adapted to be positioned along the longitudinal axis of the mould, and
- c) means for expanding the expandible means perpendicularly to the longitudinal axis of the mould.

25 The process according to the invention may further be combined with the axial compaction process envisaged in European Patent Application 407028, thus allowing the formation of compacted annuli one on top of the other. When axial compaction is used the process must also include rotation of the compact relative to the expandible means of the mould in order to release the compact from the mould.

The process of the invention has the advantage that it produces medicament

compacts having a more uniform density than compacts produced by prior art processes. In particular the density of the material at a given radius from the longitudinal axis of the compact will be the same throughout the compact, although the density at different radii need not be the same, such medicament compacts are novel. Medicament 5 compacts having such a density distribution are advantageous in that sequential volumes of medicament abraded from the compact, e.g. by the device disclosed in European Patent Application 407028, will have similar masses, thus resulting in improved uniformity of dose administered to the patient.

The process is also advantageous in that it allows medicament compacts to be 10 produced in a single rather than a multi-step compaction procedure, it also allows the production of longer compacts having a more uniform density distribution. The process also ensures good adhesion of the medicament to the wall of the powder chamber, this is advantageous when the medicament is formed in a mould which subsequently form all or part of the medicament reservoir of an inhalation device since it prevents the 15 compact slipping during abrasion.

According to further aspect of the invention we provide a compact of powdered inhalation medicament characterised in that the density at all points at a given radius from the longitudinal axis of the compact is substantially the same.

Furthermore, we provide a compact of powdered inhalation medicament, 20 obtainable by a process comprising the steps of:

- a) positioning expandible means along the longitudinal axis of a mould;
- b) placing loose powdered medicament in the mould; and
- c) expanding the expandible means perpendicularly to the longitudinal axis of the mould.

25 Medicament compacts according to these further aspects of the invention will usually be annular, i.e. cylindrical with a cylindrical inner space. The radial thickness of the medicament in such a medicament compact is preferably in the range of 0.2 to 20 mm, more preferably 0.5 to 5 mm, for example 2 mm. The cylindrical inner space preferably has a diameter of more than 10 mm and preferably less than 100 mm, for 30 example 20 mm.

The length of the medicament compact will depend on its intended use and the number of doses of active ingredient it contains. For administration from a device as disclosed in European Patent Application No. 407028, a suitable length will be in the

range 5 to 50 mm, e.g. 20 mm.

Active ingredients which may be incorporated in compacts according to the invention include any active ingredients which are conventionally administered by inhalation in powdered form. Such active ingredients include drugs for use in the prophylactic or remedial treatment of reversible obstructive airways disease. Specific active ingredients which may be mentioned include salts of cromoglycic acid, e.g. sodium cromoglycate; salts of nedocromil, e.g. nedocromil sodium; inhaled steroids such as beclomethasone dipropionate, tipredane, budesonide and fluticasone; anticholinergic agents such as ipratropium bromide; bronchodilators, e.g. salmeterol, salbutamol, reproterol, terbutaline, isoprenaline and fenoterol, and salts thereof. If desired a mixture of active ingredients, for example, a mixture of sodium cromoglycate and a bronchodilator, such as salbutamol, reproterol, isoprenaline, terbutaline, fenoterol or a salt of any one thereof, may be used.

Other active ingredients that may be mentioned include antihistamines, e.g. clemastine, pentamidine and salts thereof, acetyl- $\beta$ -methylcholine bromide; peptide hormones, e.g. insulin and amylin; bradykinin antagonists; PLA<sub>2</sub> inhibitors; PAF antagonists; lipoxygenase inhibitors; leukotriene antagonists; CNS active drugs, e.g. NMDA antagonists, glutamate antagonists, CCK agonists and antagonists; macrolide compounds, e.g. FK 506, rapamycin, cyclosporin and structurally related compounds; vitamins; vaccines, e.g. MMR vaccine and polio vaccine; and vectors for gene therapy, e.g. plasmids containing genes intended to correct genetic disorders such as cystic fibrosis.

The particles of active ingredient incorporated into the medicament compacts according to the invention preferably have a mass median diameter in the range 0.01 to 15  $\mu\text{m}$ . We prefer that at least 80% w/w and preferably at least 90% w/w of the particles of active ingredient are less than 20  $\mu\text{m}$ , more preferably less than 10  $\mu\text{m}$ , especially less than 7  $\mu\text{m}$  in diameter. The proportion of particles of active ingredient having a diameter in the range 2 to 15  $\mu\text{m}$  is preferably more than 80% w/w.

The particulate active ingredient may be prepared by any suitable technique, as will be known to those skilled in the art. Suitable techniques include milling, e.g. using a hammer or fluid energy mill, micronisation, spray drying and freeze drying.

The medicaments to be compacted according to the invention may comprise a solid pharmaceutically acceptable carrier substance in addition to an active ingredient.

The carrier preferably has an effective particle size of from 10 to 100  $\mu\text{m}$ .

The term "effective particle size" is used to denote the apparent particle size of a body without distinction as to the number of individual particles which go to make up that body i.e. no distinction is made between a single particle of given size and an 5 agglomerate of the same size which is composed of finer individual particles.

The solid pharmaceutically acceptable carrier in the medicament will generally be a non-toxic material chemically inert to the active ingredient but may, if so desired, also comprise larger particles of the active ingredient. Examples of carriers which may be used in the medicament compacts include dextrans, glucose, mannitol and lactose.

10 A particularly preferred carrier is crystalline lactose.

The particulate carrier may be prepared by grinding the carrier and subsequently separating out the desired fraction by conventional methods, e.g. by air classification and sieving.

15 The medicament may be prepared by mixing the ingredients together in a mixer, e.g. a planetary or other stirred mixer, prior to formation of the compact according to the process of the invention.

When the medicament comprises a solid carrier, we prefer the proportion of active ingredient to be from 0.1 to 70% w/w, more preferably from 0.1 to 55% w/w, and especially from 5 to 50% w/w of the medicament.

20 The medicament compacts according to the invention may also contain other ingredients such as flavouring agents, sweetening agents or colourants.

Any conventional pharmaceutically acceptable flavouring agents may be used, particular flavouring agents which may be mentioned include volatile oils, e.g. peppermint oil; and menthol. The proprietary product known by the tradename 25 Dentomint, which contains both peppermint oil and menthol, may also be used. We prefer the flavouring agent to be peppermint oil BP/Ph. Eur.

We prefer the flavouring agent to be a polysaccharide entrapped flavouring agent such as those disclosed in International Patent Application No. PCT/GB93/00503. Polysaccharide entrapped flavouring agents are advantageous for use in the compacts 30 produced according to the invention since they are sufficiently resilient to sustain the compression forces required to produce the medicament compacts without releasing the flavouring agent entrapped therein to any significant extent.

Sweetening agents which may be used include any conventional sweetening

agents, particular sweetening agents which may be mentioned include saccharin sodium, mannitol, aspartame, cyclamates and sugar.

The medicament compacts produced according to the invention preferably contain a plurality of doses of active ingredient. The actual number of doses incorporated into the compacts will depend *inter alia* upon the length of the compact, the nature of the active ingredient and the device from which it is to be administered. However, the compacts will typically comprises from 20 to 250, e.g. 112 doses of active ingredient.

The following non-limitative examples illustrate medicament compositions suitable for use in the process according to the invention:

Example 1

	<u>Ingredients</u>	% w/w
	Nedocromil sodium (milled)	50
15	Flavoured polysaccharide (85% maltodextrin : 15% peppermint oil)	5
	Lactose	to 100

Example 2

	<u>Ingredients</u>	% w/w
	Nedocromil sodium (milled)	50
	Flavoured polysaccharide (85% maltodextrin : 15% peppermint oil)	5
	Saccharin sodium	1.25
25	Lactose	to 100

Example 3

	<u>Ingredients</u>	% w/w
	Tipredane (micronised)	10
30	Lactose	to 100

The process of the invention may be adapted to form medicament compacts comprising concentric annuli of different drugs and/or carrier substances. The process

may use any number of different expandible means to achieve the desired combination of densities and annular thickness. A compact suitable for the administration of a combination drug therapy may therefore comprise a first annulus of active ingredient A, an intermediate annulus of a carrier substance, e.g. lactose, and a final annulus of active ingredient B; the intermediate annulus of carrier substance serving to separate the two active ingredients thus preventing unwanted interactions which may occur during storage. Combination drug therapy compacts may contain, for example, a mixture of sodium cromoglycate and a bronchodilator, such as salbutamol or reproterol.

The shape of the expandible means may also be changed so as to form annuli of different configurations, for example, with internal spaces of elliptical cross section. The internal walls of the compact may also be tapered, thereby forming medicament compacts in which the dose of medicament is gradually increased or decreased as subsequent doses are administered. As a further alternative medicament compacts comprising radial segments of different drugs and/or carrier substances may be produced.

The invention will now be described, by way of example only, with reference to the accompanying drawings, in which:

Figure 1 is a longitudinal section of an apparatus for performing the process according to the invention;

Figure 2 is a sectional view on the line II-II of Figure 1;

Figures 3 to 8 schematically show the production of a medicament compact according to the process of the invention;

Figures 9a) and 9b) show perspective views of different medicament compacts produced according to the invention;

Figures 10a) and 10b) show vertical sections of the medicament compacts of Figures 9a) and 9b) respectively.

Referring firstly to Figures 1 and 2: the compaction apparatus (1) is supported on a base plate (2) which is mounted on a vibratory unit (not shown). A central shaft (3) is fitted into the base plate and locked in position by the housing (4) for air port (P<sub>1</sub>). Housing (5) defining a cylindrical space (6) is fitted around central shaft (3). Moulding chamber (7) is supported within housing (5) on three radially spaced pegs, only one of which is illustrated, (8).

A cylindrical expandible mandrel (9) comprising six radially moveable segments

(10) is positioned on central shaft (3). A cylindrical elastomeric sleeve (11) is fitted over segments (10). The ends of elastomeric sleeve (11) have a protruding lip (12, 13) which fits over the ends of segments (10), this helps to prevent uneven thinning of the sleeve (11) during expansion of the mandrel (9). The inner surface of moulding chamber (7) and the outer surface of the elastomeric sleeve (11) define the sides of the annular space (14) within which the medicament is compacted.

Pistons (15, 16) are slidably mounted on central shaft (3) and are driven by pressure differences across the piston heads (17, 18). The pistons (15, 16) slide against the inside of the segments (10) to achieve expansion of the mandrel.

10 Funnel (19) is removably attached to the top of housing (5) and can be clamped to the upper surface of the housing (5) under the action of vacuum ( $V_1$ ).

Shroud (20), which provides the upper limiting face for compacting space (15), is removably attached to the upper surface of the housing (5) and can be held in position under the action of vacuum ( $V_2$ ).

15 Referring now to Figures 3 to 8 which illustrate the production of a medicament compact:

The expandible mandrel (9) is positioned along the longitudinal axis of the inner space (6) within housing (5) and a low pressure, e.g. 0.5 bar, is applied to air port ( $P_2$ ) to give a positive pressure inside the elastomeric sleeve (11) - Figure 3.

20 Moulding chamber (7) defining a cylindrical inner space is then fitted into housing (5) over the expandible mandrel (9) - Figure 4.

Filling funnel (19) is fitted onto the moulding chamber (7) and vacuum ( $V_1$ ) is turned on - Figure 5.

25 The vibratory system (not shown) is switched on and a known mass of loose powdered medicament (21) is metered into compacting space (14) between the elastomeric sleeve (11) and moulding chamber (7). The moulding chamber (7) is then vibrated until the powder settles to its "tapped density" - Figure 6.

Shroud (20) is then fitted onto the housing (5) and allowed to drop onto the surface of the powder. The vibratory system is switched off and vacuum ( $V_2$ ) turned on 30 to clamp shroud (20) in position - Figure 7.

High pressure, e.g. 10 bar, is applied to central shaft (3) via air port ( $P_1$ ) thus increasing the air pressure behind piston heads (17, 18) and driving pistons (15, 16). The pistons (15, 16) slide against the inside of segments (10) and expand mandrel (9),

thus reducing the radial separation of elastomeric sleeve (11) from the walls of moulding chamber (7) and compacting the medicament. The air pressure applied to the air port ( $P_2$ ) is then increased, e.g. to 5 bar, to inflate the elastomeric sleeve (11) and make the powder compact more circular - Figure 8.

5 The air supply ( $P_1$ ) is then turned off reducing the pressure on pistons (15, 16) and the internal pressure applied to air port ( $P_2$ ) reduced to e.g. 0.5 bar. Both vacuum supplies ( $V_1$ ,  $V_2$ ) are also turned off. The shroud (20) and funnel (19) are then removed, leaving the medicament compact (22) in moulding chamber (7). Moulding chamber (7) with medicament compact (22) therein may then be removed from the  
10 housing (5) and assembled directly into a medicament inhalation device.

Figures 9a) and 10a) show a medicament compact (23) suitable for use in combination therapy. Three consecutive radial compressions are used to form an annulus of drug A (24), followed by an annulus of lactose (25), and finally an annulus of drug B (26).

15 Figures 9b) and 10b) show a medicament compact where the dose of drug gradually increases on passing down the medicament compact. A tapered expandible means is used to form a tapered annulus of the carrier lactose (27), followed by a non-tapered expandible means to form an annulus of drug A (28).


CLAIMS

1. A process for the production of a medicament compact, which comprises the steps of:
  - a) positioning expandible means along the longitudinal axis of a mould;
  - 5 b) placing loose powdered medicament in the mould; and
  - c) expanding the expandible means perpendicularly to the longitudinal axis of the mould.
2. A process according to Claim 1, wherein the expandible means is an expandible mandrel.
- 10 3. A process according to Claim 2, wherein the expandible mandrel is a cylindrical mandrel comprising a plurality of segments capable of radial movement.
4. A process according to Claim 3, wherein the mandrel has the same number of segments as there are doses in a 360° rotation about the longitudinal axis of the compact produced by the process.
- 15 5. A process according to any one of the preceding claims, wherein the expandible means is covered by an elastomeric sleeve.
6. A process according to Claim 5, wherein the elastomeric sleeve comprises a natural rubber or a silicon rubber compound.
7. A process according to Claim 5 or 6, wherein the elastomeric sleeve can be 20 inflated relative to the expandible means.
8. A process according to any one of the preceding claims, wherein the expandible means is expanded by the action of air driven pistons.
9. A process according to any one of the preceding claims, wherein the medicament compact is formed in a mould which subsequently forms all or part of the medicament 25 reservoir of a medicament inhalation device.
10. An apparatus for the production of a medicament compact from loose powdered medicament which comprises:
  - a) a mould having a longitudinal axis adapted to receive loose powdered medicament,
  - 30 b) expandible means adapted to be positioned along the longitudinal axis of the mould, and
  - c) means for expanding the expandible means perpendicularly to the longitudinal axis of the mould.

11. A compact of powdered inhalation medicament characterised in that the density at all points at a given radius from the longitudinal axis of the compact is substantially the same.
12. A compact of powdered inhalation medicament, obtainable by a process comprising the steps of:
  - a) positioning expandible means along the longitudinal axis of a mould;
  - b) placing loose powdered medicament in the mould; and
  - c) expanding the expandible means perpendicularly to the longitudinal axis of the mould.


1/6

Fig. 1.



2/6

Fig. 2.



3/6

Fig. 3.





Fig. 4.



4/6

Fig. 5.





Fig. 6.



5/6





Fig. 7.

Fig. 8.



6/6

Fig. 9.





Fig. 10.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 93/01375

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 B30B11/00; B30B15/02

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols
Int.Cl. 5	B30B ; B22F

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched<sup>8</sup>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	GB,A,881 701 (IMPERIAL CHEMICAL INDUSTRIES) 8 November 1961 see the whole document ---	1-2,8, 10-12
Y		3-6
X	FR,A,1 346 567 (ALLMANNA SVENSKA ELEKTRISKA) 12 November 1963 see page 2, right column, paragraph 2 - page 3, left column, line 27; figures 1-4 ---	1,10
Y		3-6
X	PATENT ABSTRACTS OF JAPAN vol. 15, no. 203 (M-1116)24 May 1991 & JP,A,30 55 206 ( TAIYO SEIMITSU KK. ) 11 March 1991 see abstract ---	1,10
A		5-7 -/-

<sup>10</sup> Special categories of cited documents :<sup>10</sup>

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search  30 SEPTEMBER 1993	Date of Mailing of this International Search Report  15.10.93
International Searching Authority  EUROPEAN PATENT OFFICE	Signature of Authorized Officer  VOUTSADOPoulos K.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	EP,A,0 381 499 (DANLY INTERNATIONAL S A) 8 August 1990 see claims; figures ---	1,10
X	US,A,4 039 703 (KAMIJO ET AL.) 2 August 1977 see abstract; figures 2A-2C ---	1,10
A	EP,A,0 407 028 (FISONS PLC) 9 January 1991 cited in the application see claims; figures -----	1,10-12

ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.

GB 9301375  
SA 75984

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

30/09/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
GB-A-881701		None		
FR-A-1346567		None		
EP-A-0381499	08-08-90	CA-A-	2007683	03-08-90
		US-A-	5094548	10-03-92
US-A-4039703	02-08-77	JP-C-	1178555	30-11-83
		JP-A-	50148472	28-11-75
		JP-B-	58008888	18-02-83
		JP-A-	50077410	24-06-75
		JP-A-	50077413	24-06-75
		JP-A-	50077414	24-06-75
		CA-A-	1058814	24-07-79
		FR-A,B	2250633	06-06-75
EP-A-0407028	09-01-91	CA-A-	2017883	30-11-90
		JP-A-	3018376	25-01-91
		US-A-	5176132	05-01-93